SCHEMBL23937876

SCHEMBL23937876

CNC(=O)c1ncn2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 1/20 0.40
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
SYK P43405 1/20 0.37
KCNH2 Q12809 1/20 0.37
EGFR P00533 2/20 0.37
NTRK1 P04629 1/20 0.37
SRC P12931 1/20 0.37
EGLN1 Q9GZT9 1/20 0.36
PIN1 Q13526 1/20 0.36
BAZ2B Q9UIF8 1/20 0.36
EIF2AK3 Q9NZJ5 1/20 0.35
EIF2AK4 Q9P2K8 1/20 0.35
GAA P10253 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
PDE10A Q9Y233 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10672018 0.84 MAPT (0.48) IDO1TDO2GAACYP1A2CYP3A4
SCHEMBL25111330 0.84 IDO1 (0.38) IDO1TDO2CYP1A2CYP3A4MAPT
SCHEMBL15596028 0.81 BAZ2B (0.41) IDO1TDO2BAZ2B
SCHEMBL2743132 0.81 KDM4E (0.46) IDO1GAAMAPT
SCHEMBL13578088 0.80 CNR2 (0.54) EGLN1CYP3A4
SCHEMBL415747 0.80 TSHR (0.42) IDO1TDO2GAACYP3A4MAPT
SCHEMBL13578085 0.79 CNR2 (0.51)
SCHEMBL2631241 0.78 ELANE (0.41) IDO1TDO2CYP1A2CYP3A4MAPT
SCHEMBL26930782 0.78 NPC1 (0.46) MAPT
SCHEMBL25482800 0.77 ALDH1A1 (0.46) IDO1TDO2BAZ2BGAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083897-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF HIBERCELL, INC. 2024-03-14 US claimed
WO-2024130095-A9 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-08-02 WO disclosed
US-20240083897-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF HIBERCELL, INC. 2024-03-14 US disclosed
EP-4281182-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF Hibercell, Inc. (US) 2023-11-29 EP disclosed
WO-2022159746-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF HIBERCELL, INC. (US) 2022-07-28 WO disclosed
EP-3399968-B1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LTD (KY) 2021-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083897-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF EIF2AK4, GCN1, CLN6 YTHDC1 3901/4885IDO1 4654/4885TDO2 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.